Degeneration of defined populations of central nervous system neurons contributes to the extra-pyramidal deficits and memory loss observed in patients with Alzheimer's Disease (AD) and Parkinson's Disease (PD). The molecular and cellular mechanisms resulting in neuron death in AD and PD are poorly understood. Preliminary data suggests that anomalies in the neuronal signal transduction pathways may be involved. The hypothesis to be tested is that neuronal signal transduction pathways are abnormal in neurodegenerative diseases and contribute to their pathogenesis. In particular, we propose to examine in detail the signal transduction pathways involving phospholipid-derived second messengers, and their role in AD and PD. In order to test the central hypothesis of this application, the following aims are proposed.
Aim 1 will determine the quantitative changes in the phospholipase C signal transduction pathway in defined populations of central nervous system neurons from postmortem tissues of Ad, PD, and age-matched control patients. Phospholipase C substrates (polyphosphoinositides) and its end-products (diacylglycerol and inositol trisphosphate) will be quantitated by gas chromatography electron-capture detection and immunoassay. Phospholipase C levels will be quantitated and localized using biochemical, immunological, immunohistochemical, and molecular techniques.
Aim 2 will quantitate the changes in the phospholipase A2 pathway in AD, PD and control brains. Phospholipase A2 substrates (phospholipids), end- products (unesterified fatty acids including arachidonic acid, as lysophospholipids), and arachidonic acid metabolites (cyclooxygenase and lipoxygenase pathways) will be measured with a combination of gas chromatography, mass spectrometry, and enzyme-immunoassays. Phospholipases A2 isoforms (low or high-molecular weight), cyclooxygenases and lipoxygenases will be identified and localized.
Aim 3 will examine the regulatory components of the phospholipases signal transduction pathways in AD, PD and control brains. In particular, heterotrimeric G-proteins will be identified and localized by antibody- based and molecular methods.
Aim 4 will determine the role of sphingomyelin hydrolysis and ceramide accumulation in neuronal death.
Aim 5 will determine whether neuronal signal transduction pathways are abnormal in transgenic mice expressing a NFH/LacZ fusion protein and which accumulate Lewy Body-like inclusions in mesencephalic and telencephalic neurons as a function of age.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG009215-08
Application #
6234250
Study Section
Project Start
1997-05-15
Project End
1998-04-30
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
8
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2015) Pattern of extrapyramidal signs in Alzheimer's disease. J Neurol 262:2548-56
Paumier, Katrina L; Luk, Kelvin C; Manfredsson, Fredric P et al. (2015) Intrastriatal injection of pre-formed mouse ?-synuclein fibrils into rats triggers ?-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 82:185-199
Kalia, Lorraine V; Lang, Anthony E; Hazrati, Lili-Naz et al. (2015) Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72:100-5
Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405-12
Motsinger-Reif, Alison A; Zhu, Hongjie; Kling, Mitchel A et al. (2013) Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. Acta Neuropathol Commun 1:28
Arnold, Steven E; Toledo, Jon B; Appleby, Dina H et al. (2013) Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J Comp Neurol 521:4339-55
Kaddurah-Daouk, R; Zhu, H; Sharma, S et al. (2013) Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry 3:e244
Couthouis, Julien; Hart, Michael P; Erion, Renske et al. (2012) Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 21:2899-911
Hu, William T; Holtzman, David M; Fagan, Anne M et al. (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79:897-905
Chen-Plotkin, Alice S; Unger, Travis L; Gallagher, Michael D et al. (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 32:11213-27

Showing the most recent 10 out of 208 publications